Biological and clinical effects of anti-TNFα treatment
Section snippets
TNFα antagonists are different in the mechanism of action and they are efficacious in the treatment of chronic inflammatory diseases
Infliximab and adalimumab are both anti-TNFα monoclonal, the first being a chimeric human-murine antibody, while the latter a fully human antibody. Both agents are specific for TNFα; they do not bind lymphotoxin α (LTα). Etanercept is a fusion protein made up of the extracellular domain of the p75 TNF receptor (CD120b) and the hinge and Fc domains of human IgG1.
Infliximab binds soluble and cell-surface TNFα [1]; each infliximab molecule is capable of binding two TNF molecules, and up to three
TNFα antagonists are able to induce the synthesis of autoantibodies
Among biological effects of TNF antagonists, the production of new autoantibodies has been emphasized. Several studies focused on the appearance of autoantibodies in the RA patients sera after anti-TNF treatment.
The pathogenesis of these antibodies is not fully understood. It seems these antibodies are not correlated with the disease background, since ANA and anti-dsDNA induction is observed in RA as well as in SpA patients. Several possible explanations for the induction of ANA during anti-TNF
TNFα antagonists are able to reduce the synthesis of autoantibodies
Recent studies have reported, after 3–12 months of anti-TNFα treatment in RA patients, a significant reduction in the serum titre of RF and anti-CCP in correlation with clinical improvement [35], [36], [37], [32]. Other studies showed a reduction in IgM-RF titres alone, arguing that RF and anti-CCP antibodies are independent autoantibody systems in RA [23]. These conflicting results may be due, at least in part, to the different periods of follow-up and to the methods used to measure the
Conclusion
The TNF antagonists represent a significant advance in the therapy of active RA and others chronic inflammatory diseases. However, they have distinct biological, clinical, and pharmacological properties, that must be considered when selecting a drug for therapy. Differences in the efficacy profiles of anti-TNF are likely related to the pathophysiology of the diseases (e.g. role of lymphotoxin) as well as drug characteristics (e.g. dosing, pharmacokinetics, immunogenicity, ability to block
Acknowledgement
This work has been supported by a grant from MIUR-PRIN; Grandi Progetti d'Ateneo, La Sapienza; Fondazione U. Di Mario.
Take-home messages
- •
TNFα antagonists are efficacious in the treatment of many chronic inflammatory diseases, as demonstrated in several randomized clinical trials and open label experience, showing clinical and radiological improvement in treated patients. The different mechanism of action between monoclonal antibodies (infliximab and adalimumab) and soluble receptor (etanercept)
References (40)
- et al.
Anti-TNF therapies in the management of acute and chronic uveitis
Cytokine
(2006) - et al.
Drug-induced systemic lupus erythematosus associated with etanercept therapy
Lancet
(2002) Molecular differences in anticytokine therapies
Clin Exp Rheumatol
(2003)- et al.
Binding and functional comparisons of two types of tumor necrosis factor antagonists
J Pharmacol Exp Ther
(2002) - et al.
Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial
Ann Intern Med
(1999) - et al.
TEMPO study investigators. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial
Lancet
(2005) - et al.
Long-term safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis
J Rheumatol
(2005) - et al.
Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group
N Engl J Med
(2000) - et al.
Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial
Arthritis Rheum
(2004) - et al.
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial
Arthritis Rheum
(2005)
Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed
Ann Rheum Dis
Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial
Arthritis Rheum
Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis)
J Rheumatol
Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial
Arthritis Rheum
Adalimumab (Humira®) is effective in patients who have previously been treated with TNF-antagonists (etanercept and/or infliximab) in widespread clinical practice: 12-week outcomes in the ReAct trial
Ann Rheum Dis
The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment
Arthritis Rheum
Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety
J Rheumatol
Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT)
Arthritis Rheum
Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha
N Engl J Med
The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study
Arthritis Rheum
Cited by (106)
Antihistone and antispliceosome antibodies
2020, Systemic Lupus Erythematosus: Basic, Applied and Clinical AspectsCavitating Pulmonary Nodules in a Patient Receiving Anti-TNF
2018, Archivos de BronconeumologiaAnti-TNFα agents for refractory cystoid macular edema associated with non-infectious uveitis: A case report
2017, Journal Francais d'OphtalmologieCharacterization of TNF-α– and IL-17A–Mediated Synergistic Induction of DEFB4 Gene Expression in Human Keratinocytes through IκBζ
2016, Journal of Investigative DermatologyVasculitis induced by infliximab
2015, Indian Journal of Rheumatology